NCT00076726View on ClinicalTrials.gov

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis

PHASE2TerminatedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

July 31, 2005

Conditions
Giant Cell Arteritis
Interventions
DRUG

Infliximab

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

lead

Centocor, Inc.

INDUSTRY

NCT00076726 - A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis | Biotech Hunter | Biotech Hunter